CN1579520A - Preparation for eliminating thrombus and promoting lactation, and its preparation method - Google Patents
Preparation for eliminating thrombus and promoting lactation, and its preparation method Download PDFInfo
- Publication number
- CN1579520A CN1579520A CN 200410042502 CN200410042502A CN1579520A CN 1579520 A CN1579520 A CN 1579520A CN 200410042502 CN200410042502 CN 200410042502 CN 200410042502 A CN200410042502 A CN 200410042502A CN 1579520 A CN1579520 A CN 1579520A
- Authority
- CN
- China
- Prior art keywords
- radix
- group
- extraction
- ethanol
- channels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000007536 Thrombosis Diseases 0.000 title claims abstract description 73
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000001737 promoting effect Effects 0.000 title description 5
- 230000006651 lactation Effects 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000003814 drug Substances 0.000 claims abstract description 57
- 239000000284 extract Substances 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 27
- 239000011347 resin Substances 0.000 claims abstract description 19
- 229920005989 resin Polymers 0.000 claims abstract description 19
- 238000000605 extraction Methods 0.000 claims abstract description 18
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 15
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 11
- 238000000194 supercritical-fluid extraction Methods 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 32
- 239000000843 powder Substances 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 12
- 238000002481 ethanol extraction Methods 0.000 claims description 11
- 238000010828 elution Methods 0.000 claims description 9
- 239000012567 medical material Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 238000001256 steam distillation Methods 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000000341 volatile oil Substances 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 230000001458 anti-acid effect Effects 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 239000008016 pharmaceutical coating Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 abstract description 44
- 238000003809 water extraction Methods 0.000 abstract description 3
- 244000046101 Sophora japonica Species 0.000 abstract description 2
- 235000010586 Sophora japonica Nutrition 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000748223 Alisma Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 238000007670 refining Methods 0.000 description 43
- 241000700159 Rattus Species 0.000 description 35
- 230000037396 body weight Effects 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 14
- 239000008727 tongluo Substances 0.000 description 14
- 102000007330 LDL Lipoproteins Human genes 0.000 description 13
- 108010007622 LDL Lipoproteins Proteins 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 108010049003 Fibrinogen Proteins 0.000 description 10
- 102000008946 Fibrinogen Human genes 0.000 description 10
- 229940012952 fibrinogen Drugs 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 108090000190 Thrombin Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 229960004072 thrombin Drugs 0.000 description 8
- 206010008132 Cerebral thrombosis Diseases 0.000 description 7
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 206010053567 Coagulopathies Diseases 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 241001597008 Nomeidae Species 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 241000233855 Orchidaceae Species 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- CSVGEMRSDNSWRF-UHFFFAOYSA-L disodium;dihydrogen phosphate Chemical compound [Na+].[Na+].OP(O)([O-])=O.OP(O)([O-])=O CSVGEMRSDNSWRF-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention is a medicine for thrombus eliminating and channels activating and its manufacturing method. Its character lies in: is uses chuanxiong, astragalus, red-rooted salvia root, notoginseng, cassia twig, alisma rhizome, flower of Japanese pagoda tree, curcuma root, auckandia root, hawthorn, borneol as materials, and uses 'water extraction and alcohol deposition', 'alcohol extraction', 'supercritical extraction', 'macroporous resin extraction', it can be produced into any preparation. The method extracts the effective ingredients fully, thus it can reduce the medicine dose, convenient to the sufferer to take; another aspect, the stability of the medicine is excellent, it can solves the problem that the traditional capsule is apt to be humidified.
Description
Technical field
The present invention relates to the medicine of the eliminating thrombus and removing obstruction in channels of a kind of blood circulation promoting and blood stasis dispelling, promoting the flow of QI in the collateral by warming the meridian, more particularly, it be a kind of be meidcine ' Xiaoshuan Tongluo ' of making of raw material and preparation method thereof with Chinese herbal medicine such as Rhizoma Chuanxiong, the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Notoginseng, Ramulus Cinnamomi, Rhizoma Alismatis.
Background technology
The eliminating thrombus and removing obstruction in channels preparation mainly contains effects such as blood circulation promoting living silt, promoting the flow of QI in the collateral by warming the meridian, is applicable to that blood fat increases, the dull mind that cerebral thrombosis causes, and tongue is former to harden, and speech is puckery late, asophia, hands and feet coolness, activity pain.Traditional XIAOSHUAN TONGLUO JIAONANG major part medical material adopts water extraction to extract medical material, and another part medical material then is directly to be used as medicine after pulverizing, so the medicated powder moisture absorption very easily, and dose is big, is unfavorable for that the patient uses.
Summary of the invention
The objective of the invention is to overcome the shortcoming of known eliminating thrombus and removing obstruction in channels medicine, the eliminating thrombus and removing obstruction in channels that a kind of patient of convenience uses and dose is little medicine is provided.
Raw material and weight proportion thereof that medicine of the present invention is used are as follows:
Rhizoma Chuanxiong 9-18, Radix Astragali 10-25, Radix Salviae Miltiorrhizae 6-15, Radix Notoginseng 4-10, Ramulus Cinnamomi 4-10, Rhizoma Alismatis 4-9, Flos Sophorae 2-4, Radix Curcumae 4-9, Radix Aucklandiae 2-4, Fructus Crataegi 4-9, Borneolum Syntheticum 0.2-0.5.
This has the used raw material preferred weight proportioning of medicine:
Rhizoma Chuanxiong 10-14, Radix Astragali 15-21, Radix Salviae Miltiorrhizae 8-10, Radix Notoginseng 5-7.5, Ramulus Cinnamomi 5-7, Rhizoma Alismatis 5-7, Flos Sophorae 2-4, Radix Curcumae 5-7, Radix Aucklandiae 2-4, Fructus Crataegi 5-7, Borneolum Syntheticum 0.2-0.3.
The raw material optimum weight proportioning that thing of the present invention is used:
Rhizoma Chuanxiong 12, the Radix Astragali 18, Radix Salviae Miltiorrhizae 9, Radix Notoginseng 6, Ramulus Cinnamomi 6, Rhizoma Alismatis 6, Flos Sophorae 3, Radix Curcumae 6, the Radix Aucklandiae 3, Fructus Crataegi 6, Borneolum Syntheticum 0.25.
Preparation of pharmaceutical formulations method of the present invention may further comprise the steps:
(1) Radix Astragali, extracting in water 1-5 time, each amount of water is 4-20 times of institute's extractions Radix Astragali dose, extraction time is 0.5-10 hour, filtration, merging filtrate is concentrated, is dried to driedly, and it is standby to be ground into fine powder;
(2) Rhizoma Chuanxiong, Ramulus Cinnamomi, Radix Salviae Miltiorrhizae add water and carry 1-5 time, each amount of water be the Rhizoma Chuanxiong, Ramulus Cinnamomi and the Radix Salviae Miltiorrhizae crude drug amount 4-25 that are extracted doubly, each extraction time is 0.5-5 hour, filter, merging filtrate also is concentrated into the fluid extract of relative density 1.05-1.25, adds the 1-30 10-99.5% ethanol doubly of the fluid extract total amount of extracting while hot, abundant stirring, left standstill 5-96 hour, get supernatant, reclaim ethanol, be dried to dried, be ground into fine powder, standby;
(3) Rhizoma Alismatis adds 10-99.5% ethanol extraction 1-5 time, each alcohol adding amount be the Rhizoma Alismatis crude drug amount extracted 3-25 doubly, each extraction time is 0.5-5 hour, filters, merging filtrate reclaims ethanol and also is concentrated into fluid extract (water content is below 12%), and is standby;
(4) Fructus Crataegi, Flos Sophorae add 10-99.5% ethanol extraction 1-5 time, each alcohol adding amount be the Fructus Crataegi of being extracted, Flos Sophorae crude drug amount 3-25 doubly, each extraction time is 0.5-5 hour, filter, merging filtrate reclaims ethanol and is concentrated into relative density 1.01-1.25 liquid or extractum, adds mineral acid 10-10000ml while hot, 40-100 ℃ is incubated 10-600 minute, leave standstill, abandoning supernatant, precipitation adds and is washed to PH2-7, be dried to driedly, it is standby to be ground into fine powder;
(5) Radix Notoginseng is pulverized, add the 10-99.5% ethanol extraction respectively 1-5 time, each alcohol adding amount be the Radix Notoginseng crude drug amount extracted 3-25 doubly, each extraction time is 0.5-5 hour, filter, merging filtrate reclaims ethanol to relative density 1.01-1.30 liquid, adopt absorption with macroporous adsorbent resin, with resin with extract medical material total amount 0.5-20: the ratio upper prop of 1-10,2-30 times of water gaging eluting with pseudo-ginseng weight discards water elution liquid, renew 2-30 10-99 doubly with pseudo-ginseng weight, 5% ethanol elution, collect ethanol elution, reclaim ethanol, be dried to dried, be ground into fine powder, standby;
(6) Radix Curcumae, Radix Aucklandiae powder are broken into coarse powder, extracted volatile oil in steam distillation 1-15 hour, or employing supercritical extraction, extract pressure 2-30MPa, temperature 0-100 ℃, extraction ratio 1-8%, get above extract respectively, doubly measure cyclodextrin with the 2-30 of extract and carry out enclose, lyophilization or 35-50 ℃ is dried to dried, standby;
(7) with gained dry powder and fluid extract among the step 1-6 and Borneolum Syntheticum mix homogeneously, add any or multiple blended medicinal diluent, base unit weight is dry powder and fluid extract weight 0.1-1.5 a times, mix thoroughly, be ground into fine powder or make the granule of 0.2-3mm, make various pharmaceutical preparatioies after making pharmaceutical preparation or coating then.
The described Radix Astragali, Rhizoma Alismatis, Radix Curcumae also can adopt the water extract-alcohol precipitation method of step (2) to extract.
Described Radix Notoginseng, Radix Curcumae, Radix Salviae Miltiorrhizae, the Radix Aucklandiae, Chinese scholartree stilbene, Fructus Crataegi also can adopt the ethanol extraction method of step (3) to extract.
Described Radix Salviae Miltiorrhizae also can adopt the macroporous resin adsorption method of step (5) to extract.
Described Rhizoma Chuanxiong, Ramulus Cinnamomi also can adopt the steam distillation method of step (6) or supercritical extraction method to extract.
The described mineral acid of step (4) comprises any acid of hydrochloric acid, sulphuric acid, nitric acid.
The described macroporous adsorbent resin of step (5) is selected from any macroporous resin that comprises AB-8 type, D101 type, HP-20 type, described AB-8 type resin and D101 type resin are Cangzhou precious grace chemical industry company limited production, and described HP-20 type resin is produced for Mitsubishi chemical company.
The described inclusion method of step (6) comprises saturated water solution method, supercritical ultrasonics technology, polishing, freeze-drying or spray drying method.
The described medicinal diluent of step (7) comprise starch, dextrin, Icing Sugar, mannitol and comprise the oxide of aluminum, magnesium, calcium or the antiacid material of hydroxide in one or more blended medicinal diluents.
The described pharmaceutical preparation of step (7) can be made into said any dosage form on the pharmaceutics, comprises tablet, capsule, granule, pill, powder, membrane, microcapsule, drop pill, aerosol, unguentum syrup, oral agents, mixture.
Medicine taking dose every day 2.0-2.3g of the present invention.
Advantage of the present invention and effect:
Medicine of the present invention can be used for treating blood fat and increases, and dull mind, the body of the tongue that cerebral thrombosis causes hardened, diseases such as speech is puckery late, asophia, hands and feet coolness, activity pain; The present invention is owing to adopt different extracting method to comprise water extract-alcohol precipitation, ethanol extraction to various Chinese herbal medicine, method such as supercritical extraction, macroporous resin adsorption, fully extract the active ingredient in the medicine, remove the non-medicinal impurity of part simultaneously, therefore the pharmaceutical preparation of making is under equal drug effect situation, its dose (2.0-2.3g/ day) be traditional XIAOSHUAN TONGLUO JIAONANG preparation dose (6.7g/ day) 1/3, in addition, the pressed powder good stability that method of the present invention is made, its critical relative humidity raises 5%.
The specific embodiment
Example 1
This example is that preparation eliminating thrombus and removing obstruction in channels tablet medicine concrete steps of the present invention are as follows:
(1) in the 180g Radix Astragali, adds and extract 3 times, add water 1800g at every turn, extracted 2 hours, filter, merges three times filtrate, concentrated, drying, be ground into fine powder.
(2) get 120g Rhizoma Chuanxiong, 60g Ramulus Cinnamomi, the mixing of 90g Radix Salviae Miltiorrhizae, extracting in water three times adds 2700g water at every turn, extracted 2 hours, filter, merge three times filtrate, being concentrated into relative density then is 1.25 fluid extracts, 10 times 99.5% ethanol that adds the fluid extract total amount while hot, fully stir, left standstill 24 hours, get supernatant, reclaim ethanol, dry, be ground into fine powder.
(3) get the 60g Rhizoma Alismatis, add 60% ethanol extraction three times, add 60% ethanol 600g at every turn, extracted 1 hour at every turn, filter, merge three times filtrate, reclaim ethanol, be concentrated into fluid extract (water content is below 12%);
(4) get 60g Fructus Crataegi and 30g Flos Sophorae and mix, 99.5% ethanol extraction three times adds 99.5% amount of alcohol 1800g at every turn, the each extraction 2 hours filters merging filtrate, reclaim ethanol, being concentrated into relative density is 1.20 liquid, adds 1000ml hydrochloric acid while hot, be incubated 1.5 hours, left standstill 48 hours, abandoning supernatant, it is 3 that the precipitation adding is washed to pH value, dry then, be ground into fine powder;
(5) get the 60g Radix Notoginseng and add 99.5% ethanol extraction 3 times, each alcohol adding amount is 600g, and extraction time is 1 hour, filter, merging filtrate reclaims ethanol, be concentrated into relative density to 1.05 liquid, it is encased on the filling D101 type macroporous resin absorption post, and its resin is 10: 3 with the ratio of medical material total amount, uses the water elution of 10 times of amounts of medical material weight, discard water lotion, 10 times 99.5% ethanol elution of reuse medical material weight is collected ethanol and reclaimed, and is dry then, be ground into fine powder;
(6) the 60g Radix Curcumae and the 30g Radix Aucklandiae are pulverized, mix, use steam distillation 5 hours, extract volatile oil, use the 900g cyclodextrin then, under 40 ± 5 ℃, be dried to dried to using the polishing enclose;
(7) with step (1) to step (6) gained dry powder and fluid extract and 2.5g Borneolum Syntheticum mix homogeneously, add starch 2.5g, mix thoroughly, be ground into fine powder, make tablet then.
Example 2
This example is a preparation XIAOSHUAN TONGLUO JIAONANG agent medicine of the present invention.
The raw material consumption of medicine of the present invention: Rhizoma Chuanxiong 200g, Radix Astragali 360g, Radix Salviae Miltiorrhizae 280g, Radix Notoginseng 160g, Ramulus Cinnamomi 160g, Rhizoma Alismatis 140g, Flos Sophorae 40g, Radix Curcumae 80g, Radix Aucklandiae 60g, Fructus Crataegi 100g, Borneolum Syntheticum 6g.
Preparation method is just made capsule at last with example 1.
Example 3
This example is the animal experiment of the medicine that makes by the inventive method.
Test material
Be subjected to reagent thing eliminating thrombus and removing obstruction in channels of the present invention to make with extra care capsule (XSTLJZ), clinical consumption is 3/time, every day 3 times.Specification: 0.45g/ grain, 3.59g crude drug/grain.Be that clinical consumption is 32.3g crude drug day.Positive control drug XIAOSHUAN TONGLUO JIAONANG (XSTL), be that water extraction extracts, can buy on the market, be that Northeast Asia, Jilin Pharmaceutical limited company provides authentication code: the accurate word Z10940067 of traditional Chinese medicines number, lot number: 20030505, clinical consumption is 6/time, every day 3 times, specification: the 0.37g/ grain, it is standby to be subjected to the reagent thing all to be made into the desired concn suspension with distilled water.
Animal subject Kunming kind white mice, the Wistar rat, the qualified laboratory animal of one-level, buy by the Shenyang Medical College Experimental Animal Center, the quality certification number: SCXK (the Liao Dynasty) 2003-0016: Japan large ear rabbit, people's animal feeding factory before flood buys the quality certification number by Shenyang: SCXK (the Liao Dynasty) 2003-0011.Pellet is provided by people's animal feed factory before Shenyang City's Yuhong District.The quality certification number: No. 001, (the Liao Dynasty) searching.
22-25 ℃ of experimental situation laboratory temperature, humidity 45-60%.
The reagent sodica calx, calcium hydroxide factory of Beipiao City's mineral office, lot number: 000609; Cholesterol, Beijing extensive and profound in meaning star biotechnology responsibility company limited, lot number: 20031016; Sodium cholate, China Medicine (Group) Shanghai Chemical Reagent Co.,, import packing, lot number: F20030428; Propylthiouracil, Shanghai Fosun Zhaohui Pharmaceutical Co., Ltd., lot number: 020220; Tween 80, the Dalian elegant molecular sieve agent company limited of planting, lot number: 021218; Propylene glycol, the sincere bright chemical reagent work in Shenyang City, lot number: 20030313; The triglyceride test kit, the safe clinical reagent company limited of Beijing northization, lot number: 030516; The cholesterol reagent box, the safe clinical reagent company limited of Beijing northization, lot number: 031008; The low density lipoprotein, LDL test kit, Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd., lot number: 030218; ADP (5 '-adenosine diphosphate disodium salt), Shanghai uncle bio tech ltd difficult to understand, lot number: 20010302; Thrombin, Changchun Haiwang Bio-pharmaceuticals Pharmaceutical Co, lot number: 20030601; The adrenalin hydrochloride injection, Tianjin gold credit aminoacid company limited, lot number: 0311041; The ivens orchid, Fluka company, import packing; Sodium sulfate, Shenyang chemical reagent factory, lot number: 20021010; Acetone, Shenyang chemical reagent factory, lot number: 20020214; Prothrombin time test kit (PT), registration certificate number: No. the 3040111st, state's pencil tool (examination) word 2002; Thrombin time test test kit (TT), registration certificate number: No. the 3040117th, state's pencil tool (examination) word 2002; APTT test kit (APTT), registration certificate number: No. the 3040114th, state's pencil tool (examination) word 2002; Fibrinogen content is measured test kit (FIB), registration certificate number: state's pencil tool (examination) word 2002 the 3040116th; Pentobarbital sodium, SERVA import packing, the chemical plant is known in last sea-run, lot number: 921019; Sodium hydrogen phosphate: Shenyang City's reagent one factory's lot number: 820601; Sodium dihydrogen phosphate: Shenyang City's reagent one factory's lot number: 830516.
Instrument: ISPII type semi-automatic biochemical analyzer, Dutch Rittal GmbH; The full-automatic blood flow of the FASCO-3010A survey instrument that accelerates, Weiduo Bioengineering Institute of Chongqing University; LG-PABER platelet aggregation thrombin factorial analysis instrument, Beijing generation Supreme Being company;
Test method and result
1, the refining capsular mice normal pressure hypoxia endurance test of eliminating thrombus and removing obstruction in channels (the Qi Chen chief editor. herbal pharmacology research methodology Beijing: People's Health Publisher 1993.333)
Get body weight 18～22g healthy mice, male and female half and half are divided five groups at random by body weight, blank group, the refining basic, normal, high dosage group of capsule of eliminating thrombus and removing obstruction in channels and positive control drug XIAOSHUAN TONGLUO JIAONANG group.Each group is pressed table 1 dosage gastric infusion, the blank group is given the equivalent distilled water, administration volume 0.8ml/20g body weight, successive administration 3 days was put into the airtight wide mouthed bottle of the 250ml that the 10g sodica calx is housed in advance respectively with mice in 30 minutes after the last administration, was placed with circular filter paper on the sodica calx, bottleneck is coated with vaseline, seal after putting into mice, from putting into the time to respiratory arrest, t checks the significance of each group difference with stopwatch record mice.The results are shown in Table 1.
Table 1 eliminating thrombus and removing obstruction in channels is made with extra care capsule mice normal pressure hypoxia endurance test
| Group | Number of animals (only) | Dosage (the g crude drug/kg) | Time-to-live (branch) |
| The blank group | ????10 | ????- | ????44.7±3.80 |
| The low group of XSTLJZ | ????10 | ????4.20 | ????46.0±3.83 |
| Organize among the XSTLJZ | ????10 | ????8.40 | ????49.1±8.01 * |
| The high group of XSTLJZ | ????10 | ????16.80 | ????54.6±15.53 ** |
| The XSTL group | ????10 | ????1.73 # | ????58.2±8.88 ** |
With blank group ratio
*P＜0.05
*P＜0.01
Dosage unit is g/kg
By table 1 as seen, the refining middle and high dosage group of capsule of eliminating thrombus and removing obstruction in channels can increase the time-to-live of mice normal pressure anoxia enduring, compares with the blank group, and its difference has statistical significance.Show that the refining capsule of eliminating thrombus and removing obstruction in channels can improve mouse brain and organize hypoxia-bearing capability, prolong the mice time-to-live.
The 2. refining capsular mice broken end ischemia of eliminating thrombus and removing obstruction in channels test (ten thousand Jinzhou etc. Chinese Pharmacological circular 1994.10 (1))
Get body weight 18～22g healthy mice, male and female half and half are divided five groups at random by body weight, blank group, the refining basic, normal, high dosage group of capsule of eliminating thrombus and removing obstruction in channels and positive control drug XIAOSHUAN TONGLUO JIAONANG group.Each group is pressed table 2 dosage gastric infusion, the blank group is given the equivalent distilled water, administration volume 0.8ml/20g body weight, successive administration 3 days, after the last administration 30 minutes, mice is 2mm place broken end rapidly behind ear, causes acute cerebral ischemia, with frequency of respiration and breathing persistent period before the death of stopwatch record mouse brain, t checks the significance of each group difference.The results are shown in Table 2.
The test of the refining capsular mice broken end ischemia of table 2 eliminating thrombus and removing obstruction in channels
The group number of animals dosage frequency of respiration persistent period
(only) (g crude drug (inferior) (second)
/kg)
Blank group 10-4.80 ± 2.30 9.88 ± 1.77
The low group 10 4.20 8.10 ± 3.73 of XSTLJZ
*15.19 ± 4.71
*
Group 10 8.40 9.20 ± 3.65 among the XSTLJZ
*16.42 ± 5.67
*
The high group 10 16.80 10.00 ± 3.59 of XSTLJZ
*19.87 ± 4.91
* *
XSTL organizes 10 1.73# 9.10 ± 2.81
*18.09 ± 3.86
* *
With blank group ratio
*P＜0.05
*P＜0.01
* *P＜0.001
Dosage unit is g/kg
By table 2 as seen, the refining basic, normal, high dosage group of capsule of eliminating thrombus and removing obstruction in channels can increase the frequency of respiration of the preceding mice of brain death, prolongs the mouse breathing persistent period, compares with the blank group, and its difference has statistical significance.Show that the refining capsule of eliminating thrombus and removing obstruction in channels has the effect that improves the chmice acute cerebral ischemia.
3, the refining capsular compound thrombosis derivant of eliminating thrombus and removing obstruction in channels cause the multiple cerebral thrombosis test of rat (Du Qun etc. Traditional Chinese Medicine University Of Guangzhou's journal 1999.16 (1) 38)
Get body weight 250～350g healthy rat, male and female half and half are divided into six groups at random by body weight, blank group, the refining basic, normal, high dosage group of capsule of eliminating thrombus and removing obstruction in channels and positive control drug XIAOSHUAN TONGLUO JIAONANG group.Each group is pressed table 3 dosage gastric infusion, the blank group is given the equivalent distilled water, administration volume 1ml/100g body weight, successive administration 5 days, after the last administration 30 minutes, the anesthesia of rats by intraperitoneal injection 45mg/kg pentobarbital sodium, operation separates right common carotid artery, (1.25mmol/LADP: 12.5 μ/ml thrombin: 0.1ml/100g 1mg/ml epinephrine=100: 200: 5), the blank group is injected normal saline to inject the thrombosis derivant through scalp acupuncture.After 5 minutes, inject the blue 0.5ml/100g of 0.5% ivens, after 5 minutes, broken end was got two cerebral hemispheres and is weighed rapidly, is cut into fragment, places homogenizer, adds 0.5%Na
2SO
43ml and acetone 7ml, make homogenate, sealing, place more than 60 minutes, centrifugal 10 minutes of 3000r/min gets supernatant, return to zero with normal saline, in 620nm place colorimetric, represent the order of severity of content and the cerebral thrombosis of ivens orchid with the heavy ratio of trap and brain, t checks the significance of each group difference.The results are shown in Table 3.
The refining compound thrombosis derivant of capsule of table 3 eliminating thrombus and removing obstruction in channels causes the multiple cerebral thrombosis test of rat
| Group | Number of animals (only) | Dosage (the g crude drug/kg) | The OD/ brain is heavy |
| The blank group | ????10 | ????- | ????0.021±0.010 |
| Model control group | ????10 | ????- | ????0.044±0.016 ΔΔΔ |
| The low group of XSTLJZ | ????10 | ????2.91 | ????0.037±0.013 |
| Organize among the XSTLJZ | ????10 | ????5.82 | ????0.028±0.009 * |
| The high group of XSTLJZ | ????10 | ????11.64 | ????0.022±0.009 ** |
| The XSTL group | ????10 | ????1.20 # | ????0.027±0.009 ** |
With blank group ratio
Δ Δ ΔP＜0.001 and model control group ratio
*P＜0.01
*P＜0.01
Dosage unit is g/kg.
By table 3 as seen, the content of model control group rat brain ivens orchid increases, and with blank group ratio, its difference has statistical significance, represents that compound thrombosis derivant causes the multiple cerebral thrombosis model of rat moulding success.The content of the refining middle and high dosage group of the capsule rat brain ivens orchid of eliminating thrombus and removing obstruction in channels reduces, and with the model control group ratio, its difference has statistical significance, shows that the refining capsule of eliminating thrombus and removing obstruction in channels has the effect that stops compound thrombosis derivant to cause the multiple cerebral thrombosis of rat.
4, the refining capsule of eliminating thrombus and removing obstruction in channels to high blood lipid model rat serum cholesterol, triglyceride, high density lipoprotein, the hemorheological influence of low-density lipoprotein Pseudobulbus Bletillae (Rhizoma Bletillae) (the Li Yikui chief editor. herbal pharmacology experimental methodology Beijing: People's Health Publisher 1993.P 320).
Get body weight 150～180g healthy rat, all male, be divided into six groups at random by body weight, blank group, model control group, the refining basic, normal, high dosage group of capsule of eliminating thrombus and removing obstruction in channels and positive control drug XIAOSHUAN TONGLUO JIAONANG group.Blank group hello normal diet every day, all the other are respectively organized every morning filling hello high lipoprotein emulsion (10ml/kg) and make high blood lipid model, every afternoon is except that blank group and model control group, all the other each groups are pressed table 4 dosage gastric infusion, the blank group is given the equivalent distilled water, administration volume 1ml/100g body weight, behind the successive administration 15 days, each organizes the equal fasting of rat 12 hours, after all animals anesthesia at once carotid artery get blood, press the method for test kit description, ISPII type semi-automatic biochemical analyzer is measured serum cholesterol, triglyceride, high density lipoprotein, the full-automatic blood flow of low density lipoprotein, LDL FASCO-3010A accelerates and surveys instrument mensuration hemorheological indexes, and t checks the significance of each group difference.The results are shown in Table 4, table 5.
The refining capsule of table 4 eliminating thrombus and removing obstruction in channels is to high blood lipid model rat serum cholesterol, triglyceride, high density
The influence of lipoprotein, low density lipoprotein, LDL
| Group | Number of animals (only) | Dosage (the g crude drug/kg) | Cholesterol (mmol/L) | Triglyceride (mmol/L) | High density lipoprotein (mmol/L) | Low density lipoprotein, LDL (mmol/L) |
| The blank group | ??10 | ??- | ??1.32±0.38 | ??0.60±0.18 | ??1.22±0.31 | ????1.22±0.45 |
| Model control group | ??10 | ??- | ??5.58±2.31 ΔΔ??? Δ | ??1.12±0.41 ΔΔ??? Δ | ??0.73±0.20 ΔΔ??? Δ | ????4.30±2.29 ΔΔΔ |
| The low group of XSTLJZ | ??10 | ??2.91 | ??3.44±1.56 * | ??0.69±0.23 ** | ??0.86±0.29 | ????3.39±1.75 |
| Organize among the XSTLJZ | ??10 | ??5.82 | ??3.28±2.32 * | ??0.64±0.28 ** | ??1.03±0.30 * | ????2.06±1.14 * |
| The high group of XSTLJZ | ??10 | ??11.64 | ??3.00±1.18 ** | ??0.62±0.19 ** | ??1.15±0.21 *** | ????1.68±1.51 ** |
| The XSTL group | ??10 | ??1.20 # | ??3.48±1.91 * | ??0.71±0.33 * | ??1.11±0.25 ** | ????2.22±1.73 * |
With blank group ratio
Δ Δ ΔP＜0.001 and model control group ratio
*P＜0.01
*P＜0.01
* *P＜0.001
Dosage unit is g/kg
By table 4 as seen, model control group rat blood serum cholesterol, triglyceride, low density lipoprotein, LDL raise, and high density lipoprotein reduces, and with blank group ratio, its difference has statistical significance, expression high blood lipid model rat moulding success.Eliminating thrombus and removing obstruction in channels is made with extra care the basic, normal, high dosage group of capsule rat blood serum cholesterol, triglyceride reduces, the refining middle and high dosage group of the capsule rat blood serum low density lipoprotein, LDL of eliminating thrombus and removing obstruction in channels reduces, high density lipoprotein raises, with the model control group ratio, its difference has statistical significance, shows that the refining capsule of eliminating thrombus and removing obstruction in channels has the effect of tangible reduction high blood lipid model rat fat.
The refining capsule of table 5 eliminating thrombus and removing obstruction in channels is to the influence of high blood lipid model hemorheology of rat
| Group | Number of animals (only) | Dosage (the g crude drug/kg) | Whole blood viscosity (mPa.S) | ||
| Height is cut (200/s) | In cut (30/s) | Low cut (3/s) | |||
| The blank group | ????10 | ????- | ????4.192±0.696 | ??5.158±0.895 | ????9.849±0.937 |
| Model control group | ????10 | ????- | ????5.403±0.941 ΔΔΔ | ??6.772±1.027 ΔΔ??? Δ | ???11.739±0.909 ΔΔΔ |
| The low group of XSTLJZ | ????10 | ????2.91 | ????5.078±0.976 | ??6.430±1.147 | ????11.500±0.763 |
| Organize among the XSTLJZ | ????10 | ????5.82 | ????4.494±0.879 * | ??5.661±0.640 ** | ????10.891±0.874 * |
| The high group of XSTLJZ | ????10 | ????11.64 | ????4.357±0.627 ** | ??5.534?±0.809 ** | ????10.736±0.959 * |
| The XSTL group | ????10 | ????1.20 # | ????4.456±0.643 * | ??5.573?±0.951 * | ????10.801±0.989 * |
| Group | Number of animals (only) | Dosage (the g crude drug/kg) | Plasma viscosity (mPa.S) | Erythrocyte electrophoretic time (S) | Fibrinogen (G/L) |
| The blank group | ????10 | ????- | ????1.407±0.106 | ??15.72±2.61 | ????2.403±0.705 |
| Model control group | ????10 | ????- | ????1.611±0.091 ΔΔΔ | ??20.62±3.53 ΔΔ | ????4.931±0.907 ΔΔΔ |
| The low group of XSTLJZ | ????10 | ????2.91 | ????1.513±0.082 * | ??17.92±2.98 | ????4.577±0.938 |
| Organize among the XSTLJZ | ????10 | ????5.82 | ????1.500±0.087 ** | ??16.85±3.30 * | ????3.913±0.866 * |
| The high group of XSTLJZ | ????10 | ????11.64 | ????1.467±0.094 *** | ??16.34±2.35 ** | ????3.647±0.827 ** |
| The XSTL group | ????10 | ????1.20 # | ????1.493±0.103 ** | ??16.71±2.41 ** | ????3.659±0.900 ** |
With blank group ratio
The Δ ΔP＜0.01
Δ Δ ΔP＜0.001
With the model control group ratio
*P＜0.01
*P＜0.01
* *P＜0.001
Dosage unit is g/kg
By table 5 as seen, the whole blood viscosity of model control group rat, plasma viscosity, erythrocyte electrophoretic time, Fibrinogen all have rising, and with blank group ratio, its difference has statistical significance, and it is reliable that expression this law is made rat high blood lipid model method.With the model control group ratio, eliminating thrombus and removing obstruction in channels is made with extra care Capsules group rat whole blood viscosity, plasma viscosity, erythrocyte electrophoretic time, Fibrinogen all reduction, its difference has statistical significance, shows the improve significantly effect of high blood lipid model rat blood rheological characteristic of the refining capsule of eliminating thrombus and removing obstruction in channels.
5, the refining capsular ligation rat postcava of eliminating thrombus and removing obstruction in channels cause thrombotest (Qin Junjia etc. Chinese Chinese medicine science and technology 1998.5 (3) 155)
Get body weight 260～330g healthy rat, all male, be divided into five groups at random by body weight, model control group, the refining basic, normal, high dosage group of capsule of eliminating thrombus and removing obstruction in channels and positive control drug XIAOSHUAN TONGLUO JIAONANG group.Each group is pressed table 6 dosage gastric infusion, and model control group is given equivalent distilled water, administration volume 1ml/100g body weight, successive administration 5 days, after the last administration 1 hour, each organized the anesthesia of rats by intraperitoneal injection 45mg/kg pentobarbital sodium, surgical ligation rat postcava is sewed up stomach wall 5 hours, makes rat postcava thrombus model, reopen the abdominal cavity after 5 hours, removal of thromboses is stained with the floating blood on the bolt surface of dehematizing with moistening filter paper, claims weight in wet base, put 60 ℃ of baking boxs more roasting 4 hours, the cooling back claims dry weight.T checks the significance of each group difference.The results are shown in Table 6.
The refining capsule of table 6 eliminating thrombus and removing obstruction in channels is to the thrombotic influence of rat postcava
| Group | Number of animals (only) | Dosage (the g crude drug/kg) | Thrombus weight (mg) | |
| Weight in wet base | Dry weight | |||
| Model control group | ????10 | ????- | ??33.8±26.73 | ??13.9±12.56 |
| The low group of XSTLJZ | ????10 | ????2.91 | ??14.0±12.73 * | ??5.0±4.04 * |
| Organize among the XSTLJZ | ????10 | ????5.82 | ??8.9±8.82 * | ??4.0±4.22 * |
| The high group of XSTLJZ | ????10 | ????11.64 | ??13.6±9.85 * | ??5.1±3.48 * |
| The XSTL group | ????10 | ????1.20 | ??14.0±10.11 * | ??4.9±4.05 * |
With the model control group ratio
*P＜0.05
*P＜0.01
Dosage unit is g/kg
By table 6 as seen, compare with model control group, the refining capsule of eliminating thrombus and removing obstruction in channels can reduce the thrombus weight of postcava thrombus model rat, and its difference has statistical significance.Show that the refining capsule of eliminating thrombus and removing obstruction in channels has the thrombotic effect of antagonism rat postcava.
6, the refining capsular rat of eliminating thrombus and removing obstruction in channels moving-vein bypass thrombotest (. the Qi Chen chief editor. herbal pharmacology research methodology Beijing: People's Health Publisher 1993.336)
Get body weight 300～350g healthy rat, all male, be divided into five groups at random by body weight, model control group, the refining basic, normal, high dosage group of capsule of eliminating thrombus and removing obstruction in channels and positive control drug XIAOSHUAN TONGLUO JIAONANG group.Each group is pressed table 7 dosage gastric infusion, model control group is given the equivalent distilled water, administration volume 1ml/100g body weight, successive administration 5 days, after the last administration 1 hour, each organized the anesthesia of rats by intraperitoneal injection 45mg/kg pentobarbital sodium, and it is fixing to lie on the back, separate left external jugular vein and right common carotid artery simultaneously, in polyethylene tube, put 4 of a long 6.5cm
#Surgical thread is full of the polyethylene tube of three sections connections with the heparin-saline of 50 μ/ml, then this Guan Yiduan is inserted left external jugular vein, and the other end inserts in the right common carotid artery, and open immediately bulldog clamp causes moving-vein bypass thrombus model.Accurate recording 15min, middle Herba Clinopodii takes out silk thread and weighs, and subtracting silk thread weight with gross weight is wet weight of thrombus, calculates the thrombosis suppression ratio.T checks the significance of each group difference.The results are shown in Table 7.
The influence that the refining capsule of table 7 eliminating thrombus and removing obstruction in channels forms rat suppository
| Group | Number of animals (only) | Dosage (the g crude drug/kg) | Wet weight of thrombus (g) | Suppression ratio (%) |
| Model control group | ????10 | ????- | ??25.9±9.69 | |
| The low group of XSTLJZ | ????10 | ????2.91 | ??17.4±7.06 * | ????32.8 |
| Organize among the XSTLJZ | ????10 | ????5.82 | ??14.5±10.60 * | ????44.0 |
| The high group of XSTLJZ | ????10 | ????11.64 | ??12.7±8.20 ** | ????51.0 |
| The XSTL group | ????10 | ????1.20 | ??14.8±9.7 * | ????42.9 |
With blank group ratio
*P＜0.05
*P＜0.01
Dosage unit is g/kg
By table 7 as seen, compare with model control group, the refining capsule of eliminating thrombus and removing obstruction in channels can reduce the thrombus weight of moving-vein bypass thrombus model rat, and its difference has statistical significance.Show that the refining capsule of eliminating thrombus and removing obstruction in channels has the antagonism rat to move-the thrombotic effect of vein bypass.
The refining capsule of eliminating thrombus and removing obstruction in channels to the influence of rabbit thrombin (Guo Shengdian etc. Chinese patent medicine 1997.19 (11) 37)
Get the healthy Japan large ear rabbit of body weight 2.1-2.9kg, male and female half and half are divided five groups at random by body weight, blank group, the refining basic, normal, high dosage group of capsule of eliminating thrombus and removing obstruction in channels and positive control drug XIAOSHUAN TONGLUO JIAONANG group.Each group is pressed table 8 dosage gastric infusion, the blank group is given the equivalent distilled water, administration volume 5ml/1.5kg body weight, successive administration 15 days, after the administration in the 15th day 1 hour, (anticoagulant: blood=1: 9), centrifugal 2500 changeed 15 minutes rabbit heart blood sampling 2ml, got blood plasma and tested four of thrombins by the method for test kit description: activated partial prothrombin time (APTT), Fibrinogen (FIB), prothrombin time (PT), thrombin time (TT).T checks the significance of each group difference.The results are shown in Table 8.
The refining capsule of table 8 eliminating thrombus and removing obstruction in channels is to the influence of rabbit thrombin
| Project | Group | Number of animals (only) | Dosage (g/kg) | Clotting time (s) | |
| (APTT) activated partial thromboplastin time | The blank group | ????8 | ????- | ????21.47±0.87 | |
| The low group of XSTLJZ | ????8 | ????0.12 | ????24.85±0.18 ** | ||
| Organize among the XSTLJZ | ????8 | ????0.24 | ????26.35±0.90 ** | ||
| The high group of XSTLJZ | ????8 | ????0.48 | ????28.41±0.80 ** | ||
| The XSTL group | ????8 | ????0.23# | ????24.62±0.29 ** | ||
| (FIB) fibrinogen content | Group | Number of animals (only) | Dosage (g/kg) | Clotting time (s) | FIB(g/l) |
| The blank group | ????8 | ????- | ??11.81±0.58 | ?2.54±0.17 | |
| The low group of XSTLJZ | ????8 | ????0.12 | ??13.73±1.70 | ?2.11±0.33 ** | |
| Organize among the XSTLJZ | ????8 | ????0.24 | ??15.01±2.02 | ?1.88±0.36 ** | |
| The high group of XSTLJZ | ????8 | ????0.48 | ??15.25±1.67 | ?1.76±0.22 ** | |
| The XSTL group | ????8 | ????0.23# | ??14.84±1.12 | ?1.86±0.17 ** | |
| (PT) prothrombin time | Group | Number of animals (only) | Dosage (g/kg) | Clotting time (s) | ????INR |
| The blank group | ????8 | ????- | ??5.95±0.42 ** | ??0.29±0.03 | |
| The low group of XSTLJZ | ????8 | ????0.12 | ??7.60±0.74 ** | ??0.41±0.06 | |
| Organize among the XSTLJZ | ????8 | ????0.24 | ??8.05±0.42 ** | ??0.45±0.04 | |
| The high group of XSTLJZ | ????8 | ????0.48 | ??8.54±0.79 ** | ??0.50±0.07 | |
| The XSTL group | ????8 | ????0.23# | ??8.25±0.73 ** | ??0.48±0.06 | |
| (TT) thrombin time | Group | Number of animals (only) | Dosage (g/kg) | Clotting time (s) | |
| The blank group | ????8 | ????- | ????21.70±0.74 | ||
| The low group of XSTLJZ | ????8 | ????0.12 | ????22.12±1.25 | ||
| Organize among the XSTLJZ | ????8 | ????0.24 | ????22.60±1.57 | ||
| The high group of XSTLJZ | ????8 | ????0.48 | ????23.02±0.90 | ||
| The XSTL group | ????8 | ????0.23# | ????22.71±0.65 | ||
With blank group ratio
*P＜0.01
Dosage unit is g/kg
By table 8 as seen, with blank group ratio, the refining capsule of eliminating thrombus and removing obstruction in channels can prolong the rabbit clotting time, and its difference has statistical significance, shows that the refining capsule of eliminating thrombus and removing obstruction in channels has blood coagulation resisting function.
8, the refining capsule of eliminating thrombus and removing obstruction in channels to the accumulative influence of the inductive rabbit platelet of ADP (Feng Suoan etc. Chinese herbal medicine 1997.28 (5) 291)
Get the healthy Japan large ear rabbit of body weight 2.1-2.9kg, male and female half and half are divided five groups at random by body weight, blank group, the refining basic, normal, high dosage group of capsule of eliminating thrombus and removing obstruction in channels and positive control drug XIAOSHUAN TONGLUO JIAONANG group.Each group is pressed table 8 dosage gastric infusion, the blank group is given the equivalent distilled water, administration volume 5ml/1.5kg body weight, successive administration 15 days, after the administration in the 15th day 1 hour, (anticoagulant: blood=1: 9), mixing seals rabbit heart blood sampling 3ml at once, 500 rev/mins centrifugal 5 minutes, get the ratio test glass that platelet rich plasma 300 μ l put into the band magnetic bead, residue blood mixing, 1000 rev/mins, centrifugal 8 minutes, get platelet poor plasma and put into the ratio test glass of 300 μ l, pick up counting from the platelet rich plasma taking-up, 20 minutes begin to test, test in 4 hours finishes, preheating 1 minute adds 10 μ lADP derivants, observes the platelet aggregation rate (preparation of ADP: use in 10 minutes, sodium hydrogen phosphate sodium dihydrogen phosphate preparation buffer (PH=7.4) 2mg/ml).T checks the significance of each group difference.The results are shown in Table 9.
The refining capsule of table 9 eliminating thrombus and removing obstruction in channels is to the accumulative influence of rabbit platelet
| Group | Number of animals (only) | Dosage (g/kg) | Platelet aggregation rate (%) |
| The blank group | ????8 | ????- | ????30.54+7.48 |
| The low group of XSTLJZ | ????8 | ????0.12 | ????21.70+4.39 ** |
| Organize among the XSTLJZ | ????8 | ????0.24 | ????19.20+5.35 ** |
| The high group of XSTLJZ | ????8 | ????0.48 | ????18.62+5.20 ** |
| The XSTL group | ????8 | ????0.23 | ????19.40+8.76 ** |
With blank group ratio
*P＜0.01
By table 9 as seen, with blank group ratio, the refining Capsules group of eliminating thrombus and removing obstruction in channels can reduce the rabbit platelet aggregation rate, and its difference has statistical significance, shows that the refining capsule of eliminating thrombus and removing obstruction in channels has the obvious suppression effect to the inductive platelet aggregation of ADP.
Above-mentioned table 1-table 9 data show, refining capsule of the present invention and xstl contrast, its index is not less than xstl, but the dose that the refining capsule of actual dose the present invention is traditional XIAOSHUAN TONGLUO JIAONANG 1/3.
Claims (9)
1. the medicine of an eliminating thrombus and removing obstruction in channels is characterized in that it is the medicament of being made by the following weight proportion raw material:
Rhizoma Chuanxiong 9-18, Radix Astragali 10-25, Radix Salviae Miltiorrhizae 6-15, Radix Notoginseng 4-10, Ramulus Cinnamomi 4-10, Rhizoma Alismatis 4-9, Flos Sophorae 2-4, Radix Curcumae 4-9, Radix Aucklandiae 2-4, Fructus Crataegi 4-9, Borneolum Syntheticum 0.2-0.5.
2. the medicine of eliminating thrombus and removing obstruction in channels according to claim 1 is characterized in that it is the medicament of being made by the following weight proportion raw material:
Rhizoma Chuanxiong 10-14, Radix Astragali 15-21, Radix Salviae Miltiorrhizae 8-10, Radix Notoginseng 5-7.5, Ramulus Cinnamomi 5-7, Rhizoma Alismatis 5-7, Flos Sophorae 2-4, Radix Curcumae 5-7, Radix Aucklandiae 2-4, Fructus Crataegi 5-7, Borneolum Syntheticum 0.2-0.3.
3. the medicine of eliminating thrombus and removing obstruction in channels according to claim 1 is characterized in that it is the medicament of being made by the following weight proportion raw material:
Rhizoma Chuanxiong 12, the Radix Astragali 18, Radix Salviae Miltiorrhizae 9, Radix Notoginseng 6, Ramulus Cinnamomi 6, Rhizoma Alismatis 6, Flos Sophorae 3, Radix Curcumae 6, the Radix Aucklandiae 3, Fructus Crataegi 6, Borneolum Syntheticum 0.25.
4. according to the medicine of claim 1,2 or 3 described eliminating thrombus and removing obstruction in channels, it is characterized in that described medicament is any medicament on the pharmaceutics.
5. the described medicaments preparation method of claim 4 is characterized in that may further comprise the steps:
(1) Radix Astragali, extracting in water 1-5 time, each amount of water is 4-20 times of institute's extractions Radix Astragali dose, extraction time is 0.5-10 hour, filtration, merging filtrate is concentrated, is dried to driedly, and it is standby to be ground into fine powder;
(2) Rhizoma Chuanxiong, Ramulus Cinnamomi, Radix Salviae Miltiorrhizae add water and carry 1-5 time, each amount of water be the Rhizoma Chuanxiong, Ramulus Cinnamomi and the Radix Salviae Miltiorrhizae crude drug amount 4-25 that are extracted doubly, each extraction time is 0.5-5 hour, filter, merging filtrate also is concentrated into the fluid extract of relative density 1.05-1.25, adds the 1-30 10-99.5% ethanol doubly of the fluid extract total amount of extracting while hot, abundant stirring, left standstill 5-96 hour, get supernatant, reclaim ethanol, be dried to dried, be ground into fine powder, standby;
(3) Rhizoma Alismatis adds 10-99.5% ethanol extraction 1-5 time, each alcohol adding amount be the Rhizoma Alismatis crude drug amount extracted 3-25 doubly, each extraction time is 0.5-5 hour, filters, merging filtrate reclaims ethanol and also is concentrated into the fluid extract of water content below 12%, and is standby;
(4) Fructus Crataegi, Flos Sophorae add 10-99.5% ethanol extraction 1-5 time, each alcohol adding amount be the Fructus Crataegi of being extracted, Flos Sophorae crude drug amount 3-25 doubly, each extraction time is 0.5-5 hour, filter, merging filtrate reclaims ethanol and is concentrated into relative density 1.01-1.25 liquid or extractum, adds mineral acid 10-10000ml while hot, 40-100 ℃ is incubated 10-600 minute, left standstill 5-96 hour, abandoning supernatant, precipitation adds and is washed to PH2-7, be dried to driedly, it is standby to be ground into fine powder;
(5) Radix Notoginseng is pulverized, add the 10-99.5% ethanol extraction 1-5 time, each alcohol adding amount be the Radix Notoginseng crude drug amount extracted 3-25 doubly, each extraction time is 0.5-5 hour, filter, merging filtrate reclaims ethanol to relative density 1.01-1.30 liquid, adopt absorption with macroporous adsorbent resin, with resin with extract medical material gross weight 0.5-20: the ratio upper prop of 1-10,2-30 times of water yield water elution discards water elution liquid, continuous 2-30 10-99,5% ethanol elution doubly with medical material weight, collect ethanol elution, reclaim ethanol, be dried to dried, be ground into fine powder, standby;
(6) Radix Curcumae, Radix Aucklandiae powder are broken into coarse powder, extracted volatile oil in steam distillation 1-15 hour, or employing supercritical extraction, extract pressure 2-30MPa, temperature 0-100 ℃, extraction ratio 1-8%, get above extract respectively, doubly measure cyclodextrin with the 2-30 of extract and carry out enclose, lyophilization or 35-50 ℃ is dried to dried, standby;
(7) with gained dry powder and fluid extract among the step 1-6 and Borneolum Syntheticum mix homogeneously, add any or multiple blended medicinal diluent, base unit weight is dry powder and fluid extract weight 0.1-1.5 a times, mix thoroughly, be ground into fine powder or make the granule of 0.2-3mm, make various pharmaceutical preparatioies after making pharmaceutical preparation or coating then.
6. in accordance with the method for claim 5, it is characterized in that the described mineral acid of step (4) comprises any acid of hydrochloric acid, sulphuric acid, nitric acid.
7. in accordance with the method for claim 5, it is characterized in that the described macroporous resin of step (5) comprises any resin in AB-8 type macroporous resin, D101 type macroporous resin, the HP-20 type macroporous resin.
8. in accordance with the method for claim 5, it is characterized in that the described inclusion method of step (6) comprises saturated water solution method, supercritical ultrasonics technology, polishing, freeze-drying or spray drying method.
9. in accordance with the method for claim 5, it is characterized in that the described medicinal diluent of step (7) comprise starch, dextrin, Icing Sugar, mannitol and comprise the oxide of aluminum, magnesium, calcium or the antiacid material of hydroxide in one or more blended medicinal diluents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100425027A CN100333785C (en) | 2004-05-19 | 2004-05-19 | Preparation for eliminating thrombus and promoting lactation, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100425027A CN100333785C (en) | 2004-05-19 | 2004-05-19 | Preparation for eliminating thrombus and promoting lactation, and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1579520A true CN1579520A (en) | 2005-02-16 |
| CN100333785C CN100333785C (en) | 2007-08-29 |
Family
ID=34582153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100425027A Expired - Lifetime CN100333785C (en) | 2004-05-19 | 2004-05-19 | Preparation for eliminating thrombus and promoting lactation, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100333785C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104856968A (en) * | 2015-05-27 | 2015-08-26 | 韩志强 | Traditional Chinese medicine tablet with effects of removing thrombus and dredging collaterals and preparation method thereof |
| CN105148202A (en) * | 2015-10-13 | 2015-12-16 | 哈尔滨市康隆药业有限责任公司 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation thereof |
| CN105288459A (en) * | 2015-10-13 | 2016-02-03 | 哈尔滨市康隆药业有限责任公司 | Preparation method of Xiaoshuantongluo tablets |
| CN113230347A (en) * | 2021-06-01 | 2021-08-10 | 山东省千佛山医院 | Traditional Chinese medicine composition for treating cerebral thrombosis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1368061A (en) * | 2001-01-31 | 2002-09-11 | 杨孟君 | Nano meidcine 'Xiaoshuan Tongluo' and its preparing process |
-
2004
- 2004-05-19 CN CNB2004100425027A patent/CN100333785C/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104856968A (en) * | 2015-05-27 | 2015-08-26 | 韩志强 | Traditional Chinese medicine tablet with effects of removing thrombus and dredging collaterals and preparation method thereof |
| CN104856968B (en) * | 2015-05-27 | 2018-02-09 | 韩志强 | A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof |
| CN105148202A (en) * | 2015-10-13 | 2015-12-16 | 哈尔滨市康隆药业有限责任公司 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation thereof |
| CN105288459A (en) * | 2015-10-13 | 2016-02-03 | 哈尔滨市康隆药业有限责任公司 | Preparation method of Xiaoshuantongluo tablets |
| CN113230347A (en) * | 2021-06-01 | 2021-08-10 | 山东省千佛山医院 | Traditional Chinese medicine composition for treating cerebral thrombosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100333785C (en) | 2007-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1704085A (en) | Pharmaceutical composition with immunoregulation function and method for preparing the same | |
| CN1762401A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN101612196B (en) | Chinese medicinal composition for preventing and curing heart cerebrovascular diseases and use thereof | |
| CN1891284A (en) | Chinese medicine composition, and its preparing method and quality control method | |
| CN1283281C (en) | Medicinal composition containing wild jujube seed, lucid ganoderma and ginseng leaf and its preparing process and use | |
| CN1579520A (en) | Preparation for eliminating thrombus and promoting lactation, and its preparation method | |
| CN1060657C (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN100479837C (en) | Weinakang for treating ischemic cerebrovascular disease and senile dementia and preparation method thereof | |
| CN1272026C (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1480173A (en) | Chinese herbal medicine for treating gynecology disease and its preparing method | |
| CN1879839A (en) | Mongolian medicine Baolier for treating hyperlipemia and method for preparing same | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN101028319B (en) | Chinese-medicine compound preparation against coronary heart disease and its production | |
| CN1943724A (en) | A Chinese traditional medicinal composition for treatment of migraine and its preparation method | |
| CN1310635C (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1079396A (en) | Intelligence-enhancing pharmaceutical preparation | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1310669C (en) | Medicine composition for treating chronic hepatitis and its prepn | |
| CN100502912C (en) | Medicine for treating deficiency syndrome, its preparing process and usage | |
| CN1316989C (en) | Capsule with dried human placemta and red sage root and its preparing process | |
| CN1178690C (en) | Medicine for regulating immunity and its production method | |
| CN100344309C (en) | Refining method for Liuweidihuang compound preparation by membrane technology separation | |
| CN1150918C (en) | Medicine containing active components of Panax japonicum root and preparing process thereof | |
| CN1931352A (en) | Chinese medicine composition and its prepn process | |
| CN1233359C (en) | Compound Jigucao capsule (Abrus fruticulosus Wall. ex Wight et Arn.) and its prodn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070829 |
|
| CX01 | Expiry of patent term |